头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的临床效果观察(1)
摘 要：目的 观察头孢哌酮钠舒巴坦钠对糖尿病并发尿路感染的治疗效果及不良反应。方法 选取2015年2月～2017年2月本院收治的70例糖尿病并发尿路感染患者，以抽签分组法分为观察组和对照组，每组35例。对照组予以甲磺酸左氧氟沙星治疗，观察组予以头孢哌酮钠舒巴坦钠治疗，比较两组患者的治疗效果和不良反应情况。结果 观察组患者治疗总有效率为94.29%，高于对照组的71.43%，差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为5.71%，低于对照组的25.71%，差异具有统计学意义(P<0.05)。结论 头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染，疗效显著，安全性较高，值得借鉴。
关键词：头孢哌酮钠舒巴坦钠；糖尿病；尿路感染；不良反应
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.047
文章编号：1006-1959(2018)07-0139-02
, 百拇医药
Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection
LIU Mei
(Department of Pharmacy and Medicine，The Third People's Hospital of Benxi City，Benxi 117022，Liaoning，China)
Abstract：Objective To observe the efficacy and adverse reactions of cefoperazone sodium and sulbactam sodium in the treatment of diabetes complicated with urinary tract infection.Methods 70 cases of diabetes mellitus complicated with urinary tract infection in our hospital in February 2015～February 2017 were divided into the observation group and the control group，with 35 cases in each group.The control group was given levofloxacin mesylate treatment，observation group was treated with cefoperazone sodium and sulbactam sodium for treatment，compared two groups of curative effects and adverse reactions.Results The total effective rate of treatment in the observation group was 94.29%，which was higher than that of the control group 71.43%，and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.71%，which was lower than that of the control group 25.71%，and the difference was statistically significant(P<0.05).Conclusion Cefoperazone sodium and sulbactam sodium in treatment of diabetes complicated with urinary tract infection，curative effect，high safety，worthy of reference.
, 百拇医药
Key words：Cefoperazone sodium and sulbactam sodium；Diabetes mellitus；Urinary tract infection；Adverse reactions
糖尿病(diabetes mellitus，DM)是一種临床常见疾病，属于终身性的慢性疾病，近年来，在人们生活方式以及饮食结构不断变化的背景下，该病的发生率有着明显升高的趋势[1]。患者极易出现尿路感染，伴随尿路感染患者主要的临床症状是尿急、尿频以及尿痛，大大降低了患者的生活质量[2]。为了观察头孢哌酮钠舒巴坦钠对糖尿病并发尿路感染的治疗效果及不良反应，特选取本院收治的70例糖尿病并发尿路感染患者查究，汇总如下。
1资料与方法
1.1一般资料 选取2015年2月～2017年2月本溪市第三人民医院收治的70例糖尿病并发尿路感染患者，本研究经医院伦理会批准。采用抽签分组法将患者分为观察组和对照组，每组35例。观察组中，男16例，女19例，年龄32～60岁，平均年龄(46.06±13.17)岁；其中膀胱炎14例，肾盂肾炎10例，尿道炎11例。对照组中，男17例，女18例，年龄35～60岁，平均年龄(47.52±12.14)岁；其中膀胱炎15例，肾盂肾炎8例，尿道炎12例。两组患者一般资料相比，差异无统计学意义(P>0.05)，具有可比性。
1.2纳入及排除标准, 百拇医药(柳梅)
关键词：头孢哌酮钠舒巴坦钠；糖尿病；尿路感染；不良反应
中图分类号：R587.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.07.047
文章编号：1006-1959(2018)07-0139-02
, 百拇医药
Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection
LIU Mei
(Department of Pharmacy and Medicine，The Third People's Hospital of Benxi City，Benxi 117022，Liaoning，China)
Abstract：Objective To observe the efficacy and adverse reactions of cefoperazone sodium and sulbactam sodium in the treatment of diabetes complicated with urinary tract infection.Methods 70 cases of diabetes mellitus complicated with urinary tract infection in our hospital in February 2015～February 2017 were divided into the observation group and the control group，with 35 cases in each group.The control group was given levofloxacin mesylate treatment，observation group was treated with cefoperazone sodium and sulbactam sodium for treatment，compared two groups of curative effects and adverse reactions.Results The total effective rate of treatment in the observation group was 94.29%，which was higher than that of the control group 71.43%，and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 5.71%，which was lower than that of the control group 25.71%，and the difference was statistically significant(P<0.05).Conclusion Cefoperazone sodium and sulbactam sodium in treatment of diabetes complicated with urinary tract infection，curative effect，high safety，worthy of reference.
, 百拇医药
Key words：Cefoperazone sodium and sulbactam sodium；Diabetes mellitus；Urinary tract infection；Adverse reactions
糖尿病(diabetes mellitus，DM)是一種临床常见疾病，属于终身性的慢性疾病，近年来，在人们生活方式以及饮食结构不断变化的背景下，该病的发生率有着明显升高的趋势[1]。患者极易出现尿路感染，伴随尿路感染患者主要的临床症状是尿急、尿频以及尿痛，大大降低了患者的生活质量[2]。为了观察头孢哌酮钠舒巴坦钠对糖尿病并发尿路感染的治疗效果及不良反应，特选取本院收治的70例糖尿病并发尿路感染患者查究，汇总如下。
1资料与方法
1.1一般资料 选取2015年2月～2017年2月本溪市第三人民医院收治的70例糖尿病并发尿路感染患者，本研究经医院伦理会批准。采用抽签分组法将患者分为观察组和对照组，每组35例。观察组中，男16例，女19例，年龄32～60岁，平均年龄(46.06±13.17)岁；其中膀胱炎14例，肾盂肾炎10例，尿道炎11例。对照组中，男17例，女18例，年龄35～60岁，平均年龄(47.52±12.14)岁；其中膀胱炎15例，肾盂肾炎8例，尿道炎12例。两组患者一般资料相比，差异无统计学意义(P>0.05)，具有可比性。
1.2纳入及排除标准, 百拇医药(柳梅)